Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyViva Health IV golimumab Coverage Update | OpenPay…
    Ask Trek AI about this page
    CurrentViva HealthPolicy IC-0176

    Golimumab (Immgolis INTRI®, Simponi ARIA®) — Intravenous

    Customize your policy alerts

    Sign up for Viva Health Policy IC-0176 alerts

    Get alerted when Policy IC-0176 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage and prior authorization requirements for intravenous golimumab (Immgolis INTRI®, Simponi ARIA®) for indicated immune-mediated rheumatologic conditions and immune checkpoint inhibitor-related toxicities for Viva Health members.

    Policy Summary
    PayerViva Health
    PolicyGolimumab (Immgolis INTRI®, Simponi ARIA®) — Intravenous
    Policy CodePolicy IC-0176
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionSubmit prior authorization with a covered ICD-10 diagnosis from Appendix 1 and required documentation including age, baseline disease severity, prior therapy trials/failures, and HBV/latent TB screening results.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    MultipleCovered ICD-10 codes listed
    180 daysInitial PA duration
    365 daysRenewal PA validity
    J1602, J3590HCPCS codes

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    250 unitsCommon billing unit
    ≥2 yrsMin age for some indications

    Coverage and Medical Necessity Criteria

    Initial Therapy — Covered when ALL of the following universal criteria are met AND indication-specific criteria are met

    Covered when ALL of the following universal criteria are met AND indication-specific criteria are met:

    Universal requirements: Member is at least 18 years of age unless otherwise specified; member has been evaluated and screened for hepatitis B virus (HBV) infection prior to initiating treatment; member has been evaluated and screened for latent tuberculosis (TB) infection prior to initiating treatment and will receive ongoing monitoring for TB during treatment; member does not have an active infection (including clinically important localized infections); provider will confirm member will not receive live vaccines while on therapy; member is not on concurrent treatment with another biologic therapy or targeted synthetic therapy.
    Rheumatoid Arthritis (RA): Physician has assessed baseline disease severity utilizing an objective measure/tool; documented moderate to severe active disease; member has had at least a 3-month trial and failed previous therapy with ONE conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) OR member is already established on biologic or targeted synthetic therapy; prescribed in combination with methotrexate unless contraindicated or intolerant.

    FDA approved indication

    Psoriatic Arthritis (PsA): Member is at least 2 years of age; physician has assessed baseline disease severity utilizing an objective measure/tool; documented moderate to severe active disease; for predominantly axial disease or enthesitis: failure of at least a 4-week trial of ONE NSAID unless contraindicated; OR for peripheral arthritis or dactylitis: failure of at least a 3-month trial of ONE csDMARD unless contraindicated; OR member is already established on biologic or targeted synthetic therapy.

    FDA approved indication

    Ankylosing Spondylitis (AS): Physician has assessed baseline disease severity utilizing an objective measure/tool; documented active disease; adequate trial and failure of at least TWO NSAIDs over 4 weeks (in total) unless contraindicated; OR member is already established on biologic or targeted synthetic therapy.

    FDA approved indication

    Polyarticular Juvenile Idiopathic Arthritis (pJIA): Member is at least 2 years of age; physician has assessed baseline disease severity utilizing an objective measure/tool; documented moderate to severe active polyarticular disease; member has had at least a 1-month trial and failure (unless contraindicated or intolerant) of previous therapy with either oral NSAIDs OR csDMARDs (e.g., methotrexate, leflunomide, sulfasalazine) OR member is already established on biologic or targeted synthetic therapy; may be used as single agent or in combination with methotrexate.

    Orphan/FDA indication depending on age

    Management of Immune Checkpoint Inhibitor-Related Toxicities: Member has been receiving therapy with an immune checkpoint inhibitor; member has moderate or severe immunotherapy-related inflammatory arthritis; member is unable to taper corticosteroids after one week.

    Compendia recommended indication

    Continuation/Renewal Therapy — Renewal approval provided when ALL of the following are met

    Renewal approval provided when ALL of the following are met:

    General renewal requirements: Member continues to meet universal and relevant indication-specific criteria; duration of authorization has not been exceeded; absence of unacceptable toxicity from the drug (examples include serious infections, congestive heart failure, malignancy, demyelinating disorders, lupus-like syndrome, severe hypersensitivity reactions including anaphylaxis, severe hematologic cytopenias such as pancytopenia/leukopenia/neutropenia/agranulocytosis/aplastic anemia/thrombocytopenia).
    RA renewal response: Documented disease response compared to baseline (improvement in tender/swollen joint counts, reduction in C-reactive protein, improvement in patient global assessment, and/or improvement on a disease activity scoring tool such as DAS28 improvement ≥1.2 or ≥20% ACR20 or RAPID3 improvement).
    PsA renewal response: Documented improvement in signs/symptoms, imaging (X-ray, ultrasound, MRI), or disease activity scoring tool compared to baseline.
    AS renewal response:

    Dosing/Administration — Dosing specified for indications

    Dosing specified for indications

    IV dosing regimens: Rheumatoid arthritis, ankylosing spondylitis, and adult psoriatic arthritis: administer a 2 mg/kg intravenous infusion at weeks 0 and 4, then every 8 weeks thereafter; Pediatric psoriatic arthritis and polyarticular juvenile idiopathic arthritis: administer 80 mg/m2 IV at weeks 0 and 4, then every 8 weeks thereafter; Management of immune checkpoint inhibitor-related toxicities: administer a 2 mg/kg IV x 1 dose.

    Extracted dosing statements

    Initial/continued coverage — diagnosis requirement: Covered when the member has one of the following ICD-10 diagnoses documented

    Covered when the member has one of the following ICD-10 diagnoses documented

    Any one covered diagnosis code: Presence of any ICD-10 code listed in Appendix 1 (including M05.*, M06.*, M08.* series and related codes enumerated in Appendix 1) on the medical record or claim supports coverage for golimumab per this appendix; specific right/left/unspecified site variants are enumerated in the appendix.

    Specific site and modifier codes are listed in Appendix 1.

    Members with active infection, including clinically important localized infections, are excluded from initiating golimumab therapy until the infection has resolved. This is part of the Universal Criteria requiring latent TB screening and ongoing monitoring and avoidance of live vaccines prior to and during therapy.

    The NQTL Factor Checklist notes that potential for misuse/abuse is not a priority for prior authorization of golimumab; however, PA is considered for other factors such as indication, safety/efficacy, and cost. This indicates that prior authorization design did not emphasize misuse/abuse concerns in determining utilization management for this drug.

    Within the cited appendix segments there are no explicit clinical exclusions listed; the document portion shown focuses on enumerating covered ICD-10 diagnosis codes (Appendix 1) rather than listing additional exclusionary conditions.

    Medicare Part B Covered Diagnosis Codes for this policy segment are listed as N/A. The appendix indicates that Medicare NCDs/LCDs/LCAs may apply where relevant, but no specific Part B covered diagnosis codes are provided in this section.

    Concurrent treatment with another biologic therapy or a targeted synthetic therapy is not permitted while initiating or receiving golimumab, per the Universal Criteria.

    The appendix content in these chunks does not list conditions considered not medically necessary; it exclusively enumerates covered diagnosis codes that support medical necessity for golimumab when submitted on claims or prior authorization requests.

    Billing Codes, NDCs, and Diagnosis Code Lists

    Billing/HCPCS units and strength referencesHCPCS | NDC
    250 billable unitsSimponi ARIA: 250 billable units per dose (loading/maintenance or single dose for ICI-related toxicity)
    250 mgImmgolis INTRI: 250 mg per dose (loading/maintenance or single dose for ICI-related toxicity)
    HCPCS CodesHCPCSCovered
    J1602Injection, golimumab, 1 mg, for intravenous use; 1 billable unit = 1 mg
    J3590Unclassified biologics (Immgolis INTRI Only)
    NDCsNDCCovered
    57894-0350-xxSimponi ARIA 50 mg/4 mL injection, single-dose vial
    69448-0029-xxImmgolis INTRI 50 mg/4 mL injection, single-dose vial
    Covered ICD-10 Diagnosis Codes (partial list shown)ICD-10Covered
    L40.50Arthropathic psoriasis, unspecified
    L40.51Distal interphalangeal psoriatic arthropathy
    L40.52Psoriatic arthritis mutilans
    L40.53Psoriatic spondylitis
    L40.59Other psoriatic arthropathy
    M05.10Rheumatoid lung disease with rheumatoid arthritis of unspecified site
    M05.111Rheumatoid lung disease with rheumatoid arthritis of right shoulder
    M05.112Rheumatoid lung disease with rheumatoid arthritis of left shoulder
    M05.119Rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder
    M05.121Rheumatoid lung disease with rheumatoid arthritis of right elbow
    1–10 of 18
    1/2
    Covered ICD-10 Diagnosis Codes (Appendix 1)ICD-10Covered
    M05.30Rheumatoid heart disease with rheumatoid arthritis of unspecified site.
    M05.311Rheumatoid heart disease with rheumatoid arthritis of right shoulder.
    M05.312Rheumatoid heart disease with rheumatoid arthritis of left shoulder.
    M05.319Rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder.
    M05.321Rheumatoid heart disease with rheumatoid arthritis of right elbow.
    M05.322Rheumatoid heart disease with rheumatoid arthritis of left elbow.
    M05.329Rheumatoid heart disease with rheumatoid arthritis of unspecified elbow.
    M05.331Rheumatoid heart disease with rheumatoid arthritis of right wrist.
    M05.332Rheumatoid heart disease with rheumatoid arthritis of left wrist.
    M05.339Rheumatoid heart disease with rheumatoid arthritis of unspecified wrist.
    1–10 of 73
    1/8
    Covered ICD-10 Diagnosis Codes (Appendix 1)ICD-10Covered
    M05.621Rheumatoid arthritis of right elbow with involvement of other organs and systems.
    M05.622Rheumatoid arthritis of left elbow with involvement of other organs and systems.
    M05.629Rheumatoid arthritis of unspecified elbow with involvement of other organs and systems.
    M05.631Rheumatoid arthritis of right wrist with involvement of other organs and systems.
    M05.632Rheumatoid arthritis of left wrist with involvement of other organs and systems.
    M05.639Rheumatoid arthritis of unspecified wrist with involvement of other organs and systems.
    M05.641Rheumatoid arthritis of right hand with involvement of other organs and systems.
    M05.642Rheumatoid arthritis of left hand with involvement of other organs and systems.
    M05.649Rheumatoid arthritis of unspecified hand with involvement of other organs and systems.
    M05.651Rheumatoid arthritis of right hip with involvement of other organs and systems.
    1–10 of 32
    1/4
    Covered ICD-10 Diagnosis Codes (Appendix 1)ICD-10Covered
    M05.751Rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement.
    M05.752Rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement.
    M05.759Rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement.
    M05.761Rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement.
    M05.762Rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement.
    M05.769Rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement.
    M05.771Rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement.
    M05.772Rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement.
    M05.779Rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement.
    M05.79Rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement.
    1–10 of 23
    1/3
    pJIA pediatric dosing — inv-18
    pJIA pediatric IV dosing80 mg/m2 IV at weeks 0 and 4, then every 8 weeks
    Adult IV dosing (RA/AS/PsA)2 mg/kg IV at weeks 0 and 4, then every 8 weeks
    Management of ICI-related toxicities dosing2 mg/kg IV x 1 dose
    Not applicable — inv-19
    Not applicable (placeholder)No specific threshold or value applies
    Appendix 1 coverage

    Prior Authorization, Documentation, and Billing Requirements

    Prior Authorization

    Prior authorization validity

    Prior authorization is required. Initial approvals are provided for 6 months (180 days); renewals may be authorized every 12 months (365 days) thereafter when renewal criteria are met.

    Prior Authorization

    Prior authorization recommended per NQTL checklist

    Per the NQTL Factor Checklist, prior authorization should be considered for golimumab products because indication, safety/efficacy, and drug cost were identified as factors to consider for PA.

    Prior Authorization

    Include a covered diagnosis with PA

    Submit a covered ICD-10 diagnosis from Appendix 1 with prior authorization requests to support medical necessity for golimumab.

    Background and Clinical Context

    Golimumab intravenous formulations are indicated for immune-mediated rheumatologic conditions and related inflammatory syndromes. Common clinical uses documented in the policy include treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and polyarticular juvenile idiopathic arthritis (pJIA). The policy also cites use for management of immune checkpoint inhibitor-related inflammatory arthritis when patients are unable to taper corticosteroids after one week. Dosing statements in the policy note adult IV regimens (commonly 2 mg/kg IV at weeks 0 and 4, then every 8 weeks) and pediatric pJIA/PsA dosing (typically 80 mg/m2 IV at weeks 0 and 4, then every 8 weeks). Baseline and ongoing infectious risk screening (hepatitis B and latent TB) and avoidance of live vaccines are required prior to and during therapy.

    Key Definitions and Dosing Notes

    inv-37: Management of Immune Checkpoint Inhibitor-Related Toxicities — Use of golimumab for moderate to severe immunotherapy-related inflammatory arthritis
    Use caseUse of golimumab for moderate or severe immunotherapy-related inflammatory arthritis in patients receiving immune checkpoint inhibitors who are unable to taper corticosteroids after one week
    Patient contextMember must be receiving immune checkpoint inhibitor therapy
    Clinical requirementModerate or severe immunotherapy-related inflammatory arthritis documented
    inv-38: IV golimumab dosing — Adult dosing commonly 2 mg/kg IV at weeks 0 and 4, then every 8 weeks; pediatric dosing at 80 mg/m2
    Common adult IV dosing2 mg/kg IV at weeks 0 and 4, then every 8 weeks
    Pediatric IV dosing reference

    Policy Revision History

    2026-07-01Policy last reviewedLatest

    Policy last reviewed and effective date recorded as 07/01/2026; prior review history listed back to 2013.

    2013-09-05Policy originated

    Document date of origin recorded as 09/05/2013 when the policy was first created.

    2026-03-01Prior review
    Policy Summary
    PayerViva Health
    PolicyGolimumab (Immgolis INTRI®, Simponi ARIA®) — Intravenous
    Policy CodePolicy IC-0176
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionSubmit prior authorization with a covered ICD-10 diagnosis from Appendix 1 and required documentation including age, baseline disease severity, prior therapy trials/failures, and HBV/latent TB screening results.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaBilling Codes, NDCs, and Diagnosis Code ListsPrior Authorization, Documentation, and Billing RequirementsBackground and Clinical ContextKey Definitions and Dosing NotesPolicy Revision History
    Documented improvement in total back pain, physical function, morning stiffness, and/or on a disease activity scoring tool (e.g., ASDAS improvement ≥1.1 or BASDAI improvement ≥2).
    pJIA renewal response: Documented improvement such as an improvement on JADAS or ACR-Pedi criteria (e.g., ACR-Pedi 30 with at least 30% improvement in three of six variables) compared to baseline.
    Appendix 1 lists covered ICD-10 codes (M05.*, M06.*, M08.* and related codes) to support medical necessity
    Use on claims/authorizationsA covered ICD-10 diagnosis from Appendix 1 must be submitted with prior authorization requests
    Prior Authorization

    Prior authorization requires a listed Appendix 1 diagnosis

    Prior authorization and coverage requests must reference a supported ICD-10 diagnosis listed in Appendix 1; only diagnoses enumerated in the appendix are accepted for coverage consideration.

    Step Therapy

    Step therapy requirements by indication

    Document required step therapy trials and failures per indication before requesting authorization; specific minimum trial durations and agents are specified by condition.

    • Rheumatoid arthritis: ≥3-month trial and failure of ONE csDMARD (or already on biologic/targeted synthetic therapy).
    • Psoriatic arthritis: ≥4-week trial of ONE NSAID for axial disease OR ≥3-month trial of ONE csDMARD for peripheral disease (or already on biologic/targeted synthetic therapy).
    • Ankylosing spondylitis: failure of at least TWO NSAIDs over 4 weeks total (or already on biologic/targeted synthetic therapy).
    • pJIA: ≥1-month trial and failure of NSAIDs OR csDMARDs (unless contraindicated) (or already on biologic/targeted synthetic therapy).
    Documentation Required

    Perform and document required baseline screenings

    Follow universal criteria screening prior to initiation and document results in the medical record.

    • Confirm member age meets indication-specific minimums (e.g., ≥2 years for PsA and pJIA; otherwise ≥18 years unless specified).
    • Document HBV and latent TB screening prior to initiating therapy.
    Documentation Required

    Confirm absence of concurrent biologic therapy and vaccination plan

    Ensure member is not on concurrent biologic or targeted synthetic therapy and confirm live vaccines will not be administered while on golimumab.

    • Document absence of active infection and plan to avoid live vaccines during therapy.
    • Document that no concurrent biologic or targeted synthetic therapy is prescribed.
    Documentation Required

    Document ICI-related toxicity criteria

    For management of immune checkpoint inhibitor–related toxicities, document inability to taper corticosteroids after one week and membership on immune checkpoint inhibitor therapy.

    • Record that the member is receiving an immune checkpoint inhibitor and has moderate or severe immunotherapy-related inflammatory arthritis.
    • Document attempts to taper corticosteroids and inability to do so after one week.
    Documentation Required

    Documentation required for PA requests

    Include member age, a baseline disease severity assessment using an objective measure/tool, and prior therapy trials and failures in the prior authorization or medical record documentation.

    • Baseline objective disease assessment (e.g., DAS28, BASDAI, JADAS, etc.).
    • Record of prior medications and documented trial durations and reasons for failure or intolerance.
    Billing Rule

    Billing codes and NDC documentation

    Use HCPCS codes J1602 (golimumab, 1 mg IV) and J3590 (unclassified biologics for Immgolis INTRI) as applicable on claims, and include the appropriate NDC for the product billed.

    • J1602 — Injection, golimumab, 1 mg (1 billable unit = 1 mg).
    • J3590 — Unclassified biologics (Immgolis INTRI only).
    • Include NDC: Simponi ARIA 57894-0350-xx or Immgolis INTRI 69448-0029-xx as applicable.
    Billing Rule

    Required diagnosis coding (use Appendix 1)

    Record an appropriate ICD-10 diagnosis from Appendix 1 on the claim and in the medical record to support medical necessity for golimumab.

    • Appendix 1 lists covered ICD-10 codes (M05.*, M06.*, M08.*, M45.*, L40.*, etc.) that must be used to justify coverage.
    Documentation Required

    Support PA/claims with Appendix 1 diagnosis documentation

    Ensure documentation supports one of the ICD-10 codes listed in Appendix 1 when requesting prior authorization or submitting claims for golimumab.

    • Include specific code and description from Appendix 1 in the medical record and PA request.
    Denial Risk

    Denial risks for missing screenings or age noncompliance

    Prior authorization may be denied if the member does not meet age requirements, or if required HBV or latent TB screening was not performed prior to initiation, or if an active infection or concurrent biologic therapy is present.

    • Denial risk if member is under the indicated age for the condition.
    • Denial risk if HBV or latent TB screening results are absent from documentation.
    • Denial risk if active infection exists or concurrent biologic/targeted synthetic therapy is being used.
    Prior Authorization

    PA consideration and potential denial if not obtained

    Because the NQTL checklist identified indication, safety/efficacy, and cost as considerations, PA will be considered and lack of PA where required may result in denial.

    • PA is applied due to indication, safety/efficacy concerns, and drug cost per the NQTL assessment.
    Denial Risk

    Diagnosis code mismatch may trigger denial

    Claims or PA requests that do not include one of the covered ICD-10 codes listed in Appendix 1 may be subject to denial for lack of an accepted diagnosis to support golimumab coverage.

    Note

    Ensure compliance with Medicare NCDs/LCDs/LCAs where applicable

    For Medicare beneficiaries, comply with applicable Medicare NCDs, LCDs, and Local Coverage Articles (LCAs); failure to follow applicable CMS coverage determinations may affect coverage decisions.

    • Medicare Part B covered diagnosis codes in this policy segment: N/A — check applicable NCD/LCD/LCA for local requirements.
    80 mg/m2 IV at weeks 0 and 4, then every 8 weeks (for pediatric PsA and pJIA)
    Single-dose for ICI toxicity2 mg/kg IV x 1 dose for management of immune checkpoint inhibitor-related toxicities
    inv-39: Covered Diagnosis Codes (Appendix 1) — definition of codes that indicate accepted diagnoses for coverage
    DefinitionThe set of ICD-10 codes listed in Appendix 1 that, when present on the medical record and claim, indicate an accepted diagnosis for which golimumab coverage may be considered
    PurposeSupports submission of a covered diagnosis with prior authorization and claims to establish medical necessity
    ScopeIncludes multiple M05.*, M06.*, M08.* and related ICD-10-CM codes enumerated in Appendix 1
    inv-40: Covered Diagnosis Codes (Appendix 1) — additional enumeration reference
    Appendix enumerationAppendix 1 enumerates multiple ICD-10-CM codes (examples: M08.259, M08.431, M08.811, M08.952, M45.0–M45.9) that are accepted diagnoses for golimumab coverage
    Documentation expectationMedical record/claim should include one of the listed Appendix 1 codes when requesting authorization or claim payment
    Code series includedJuvenile arthritis (M08.*), ankylosing spondylitis (M45.*), and numerous rheumatoid arthritis codes (M05.*, M06.* series referenced elsewhere in appendix)
    inv-41: CMS/NCD/LCD/LCA note (Appendix 2) — Medicare coverage determination applicability note
    Medicare applicability noteMedicare NCDs/LCDs/LCAs may exist and compliance with applicable CMS policies is required where relevant for Medicare Part B claims
    Medicare Part B codesMedicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCD/LCA): N/A (no specific Part B codes listed in this appendix)
    ReferenceRefer to the CMS Medicare Coverage Database for any applicable NCD/LCD/LCA documents: https://www.cms.gov/medicare-coverage-database/search.aspx

    Policy reviewed in March 2026 as part of the document's maintained review history.

    2025-03-01Prior review

    Policy reviewed in March 2025 as listed in the document's review history.

    2024-10-01Prior review

    Policy reviewed in October 2024 as recorded in the review history.

    2023-10-01Prior review

    Policy reviewed in October 2023 as recorded in the review history.

    2022-10-01Prior review

    Policy reviewed in October 2022 as recorded in the review history.